In vivo studies have shown that salidroside improved the inflammatory response of lung tissue in rats with severe pneumonia, reduced the release of inflammatory mediators and inflammatory cell infiltration in a dose-dependent manner, and its effects were associated with reduced levels of NF-κB and p38 signaling pathway activation (Wang et al., 2021a). Here, NFKB1 is linked to susceptibility to pneumonia measurement.